Resverlogix

Resverlogix Corp. is a biopharmaceutical company focused on developing new therapies for cardiovascular diseases and related indications such as vascular inflammation and Alzheimer's disease. Its development programs include NexVas Plaque Regression, a technology platform that has completed Phase Ia safety trials of human RVX-208 and advanced to Phase Ib/IIa clinical trials aimed at developing drugs that increase ApoA-I to reduce the risk of cardiovascular disease. Apabetalone is a BET inhibitor with selectivity for the second bromodomain (BD2) within BET proteins. This selective inhibition of BD2 by apabetalone generates a specific set of biological effects, offering potentially significant benefits for patients with high-risk cardiovascular disease, diabetes, chronic kidney disease, end-stage renal disease undergoing hemodialysis, neurodegenerative diseases, Fabry disease, peripheral vascular disease, arterial diseases, and other orphan conditions, while maintaining a well-documented safety profile.